Flovent hfa and Synagis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Flovent hfa (fluticasone propionate) and Synagis (palivizumab). Common drug interactions include respiratory tract infection bacterial among females and seizure among males.

The phase IV clinical study analyzes what interactions people have when they take Flovent hfa and Synagis. It is created by eHealthMe based on reports of 86 people who take the same drugs from the FDA, and is updated regularly.

What is Flovent hfa?

Flovent hfa has active ingredients of fluticasone propionate. It is often used in asthma. eHealthMe is studying from 7,457 Flovent hfa users. Check the latest studies of Flovent hfa.

What is Synagis?

Synagis has active ingredients of palivizumab. eHealthMe is studying from 19,114 Synagis users. Check the latest studies of Synagis.



On Jul, 12, 2026

86 people who take Flovent hfa and Synagis together, and have interactions are studied.

Flovent hfa and Synagis drug interactions.

What are the common drug interactions of Flovent Hfa and Synagis, by gender? *:

female:

  1. Respiratory tract infection bacterial
  2. Rhinovirus infection
  3. Urinary tract infection
  4. Vomiting
  5. Wheezing (a high-pitched whistling sound made while you breath)
  6. Respiratory syncytial virus infection (viral disease of respiratory system)
  7. Respiratory syncytial virus bronchiolitis (a lower respiratory tract infection due to virus)
  8. Fatigue (feeling of tiredness)
  9. Viral infection
  10. Cough

male:

  1. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  2. Respiratory syncytial virus infection (viral disease of respiratory system)
  3. Lung disorder (lung disease)
  4. Rash macular (small, flat red spots)
  5. Reflux gastritis (a condition in which the lining of a person's stomach becomes inflamed as a result of exposure to bile)
  6. Retching (strong involuntary effort to vomit)
  7. Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
  8. Rhinorrhoea (watery mucus discharge from the nose)
  9. Death
  10. Respiratory syncytial virus bronchiolitis (a lower respiratory tract infection due to virus)

What are the common drug interactions of Flovent Hfa and Synagis, by age (0-1 to 60+)? *:

0-1:

  1. Respiratory syncytial virus infection (viral disease of respiratory system)
  2. Weight decreased
  3. Pneumonia
  4. Rhinovirus infection
  5. Pyrexia (fever)
  6. Pulmonary hypertension (increase in blood pressure in the lung artery)
  7. Cough
  8. Lung disorder (lung disease)
  9. Reflux gastritis (a condition in which the lining of a person's stomach becomes inflamed as a result of exposure to bile)
  10. Retching (strong involuntary effort to vomit)

2-9:

  1. Respiratory syncytial virus infection (viral disease of respiratory system)
  2. Viral infection
  3. Enterovirus infection
  4. Ill-defined disorder
  5. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  6. Respiratory tract infection bacterial
  7. Rhinovirus infection
  8. Pharyngitis streptococcal (inflammation of the pharynx caused by infection from. streptococcus)
  9. Respiratory syncytial virus bronchiolitis (a lower respiratory tract infection due to virus)
  10. Adrenocortical insufficiency acute (suddenly adrenal glands do not produce adequate amounts of steroid hormones)

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Premature Baby: 33 people, 38.37%
  2. Bronchopulmonary Dysplasia (chronic lung disorder in infants - enlargement of an organ or tissue by the proliferation of cells of an abnormal type): 20 people, 23.26%
  3. Low Birth Weight Baby: 10 people, 11.63%
  4. Chronic Respiratory Disease: 8 people, 9.30%
  5. Pulmonary Hypertension (increase in blood pressure in the lung artery): 7 people, 8.14%
  6. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 7 people, 8.14%
  7. Wheezing (a high-pitched whistling sound made while you breath): 5 people, 5.81%
  8. Lung Disorder (lung disease): 5 people, 5.81%

* Approximation only. Some reports may have incomplete information.

Do you take Flovent hfa and Synagis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Flovent hfa and Synagis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Flovent hfa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Synagis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Flovent hfa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Synagis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on fluticasone propionate and palivizumab (the active ingredients of Flovent hfa and Synagis, respectively), and Flovent hfa and Synagis (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: